ReviewClinical science (London, England : 1979)2009
Insulin resistance and hyperinsulinaemia in the development and progression of cancer.
Review in Clinical science (London, England : 1979), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 5 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Association between prediabetes and thyroid cancer risk: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Diagnostic performance of the triglyceride-glucose index in predicting occurrence of cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- The crucial role and mechanism of insulin resistance in metabolic disease.Frontiers in endocrinology · 2023Pooled it
- Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2021Pooled it
- Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.PloS one · 2016Pooled it
- Trial
- Association between HOMA-IR and Frailty among U.S. Middle-aged and Elderly Population.Scientific reports · 2019Trial
- Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions.Diabetologia · 2012Trial
- Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.Genes & diseases · 2026Review
- Targeting Insulin Resistance Through Nutrition: Pathophysiological Insights and Dietary Interventions.Nutrients · 2026Review
- A nomogram model based on CT-assessed body composition parameters for predicting postoperative recurrence in advanced gastric cancer.Abdominal radiology (New York) · 2026Article
- Body mass index has no impact on complications and mortality for patients with stage IV pancreatic ductal adenocarcinoma.Translational gastroenterology and hepatology · 2026Article
- A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.Frontiers in nutrition · 2026Article
- Implantation of engineered adipocytes suppresses tumor progression in cancer models.Nature biotechnology · 2025Article
- Excellent Patient-Provider Communication May Mitigate Racial and Ethnic Disparities in Diabetes Care Management Among Cancer Survivors.Journal of racial and ethnic health disparities · 2025Article
- Microvascular Complications and Cancer Risk in Type 2 Diabetes: A Population-Based Study.Cancers · 2025Article
- Temporal relationship between chronic inflammation and insulin resistance and their combined cumulative effect on cancer risk: a longitudinal cohort study.BMC public health · 2025Article
- Personalized Lifestyle Interventions for Prevention and Treatment of Obesity-Related Cancers: A Call to Action.Cancers · 2025Article
- Preoperative Glycosylated Hemoglobin A1C Impacts Long-Term Outcomes Following Curative-Intent Resection of Nonfunctional Gastroenteropancreatic Neuroendocrine Tumors.Journal of surgical oncology · 2025Article
- The prowess of metabolomics in cancer research: current trends, challenges and future perspectives.Molecular and cellular biochemistry · 2025Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental, epidemiological and clinical evidence implicates insulin resistance and its accompanying hyperinsulinaemia in the development of cancer, but the relative importance of these disturbances in cancer remains unclear. There are, however, theoretical mechanisms by which hyperinsulinaemia could amplify such growth-promoting effects as insulin may have, as well as the growth-promoting effects of other, more potent, growth factors. Hyperinsulinaemia may also induce other changes, particularly in the IGF (insulin-like growth factor) system, that could promote cell proliferation and survival. Several factors can independently modify both cancer risk and insulin resistance, including subclinical inflammation and obesity. The possibility that some of the effects of hyperinsulinaemia might then augment pro-carcinogenic changes associated with disturbances in these factors emphasizes how, rather than being a single causative factor, insulin resistance may be most usefully viewed as one strand in a network of interacting disturbances that promote the development and progression of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.